METHOD FOR TREATING LUMINAL SUBTYPE OF BREAST CANCER Russian patent published in 2019 - IPC A61N5/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for treating luminal subtype of breast cancer. Morphological examination is performed. There are metastatic involvement of lymph nodes. If observing at least one lymphatic metastasis, the Ki67 proliferation index in lymphogenic metastasis cells is additionally determined. If the proliferation index Ki67 in the cells of lymphogenic metastasis exceeds the Ki67 proliferation index in the primary tumor cells by more than 10 %, then 4 courses of adjuvant chemotherapy based on taxanes and adjuvanted remote radiation therapy is performed on the area of axillary lymph nodes of the third level and supra-switching lymph nodes with subsequent long-term prescription of hormonal therapy with aromatase inhibitors. If the proliferation Ki67 index in lymphogenic metastasis cells is more by 5–10 % of the Ki67 proliferation index in the primary tumor cells, then prescribed 4 courses of adjuvant chemotherapy according to doxorubicin/cyclophosphan scheme according to known scheme and adjuvanted remote radiation therapy is conducted on area of axillary lymph nodes of the third level and subclavian lymphonoduses, followed by hormone therapy with tamoxifen for 7–8 years. If the Ki67 proliferation index in lymphogenic metastasis cells exceeds the Ki67 proliferation index in the primary tumor cells by less than 5 %, then adjuvanted remote radiation therapy is prescribed for the area of axillary lymph nodes of the third level and subclavian lymph nodes with subsequent administration of tamoxifen for 5 years.

EFFECT: method provides optimization of patient's treatment by determining Ki67 proliferation index in lymphogenic metastasis cells.

1 cl, 3 ex